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Abstract: Objective: To explore the active ingredients and dose ratio of medicine, combined with the optimal dose 
ratio of Chlorogenic acid-Geniposide to treat rats with experimental fatty liver. Methods: The active ingredients and optimized 
prescription were screened out, adopting uniform design to divide Chlorogenic acid-Geniposide into six combinations, by using 
experiment on high fat diet-induced fatty liver rat models, and the pathological results were observed. The serum LDL-C, HDL-C, 
CHO, ALT, AST and liver TG were taken as the screening-indexes. Results: Compared with the normal groups, the serum 
LDL-C, CHO, ALT, AST and liver TG in model groups were significantly higher (P<0.01), the serum HDL-C in model group was 
significantly decreased (P<0.01), and the pathology of liver tissue got obvious steatosis. According to stepwise regression analysis 
of uniform design, the best ratio of Chlorogenic acid-Geniposide to anti-NAFLD were Chlorogenic acid 90mg with Geniposide 
90mg. Conclusion: Uniform design is the appropriate way to confirm the optimized prescription for active ingredient of Chinese 
medicine. 
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20130112），血清低密度脂蛋白胆固醇（low density lipoprotein 
cholesterol，LDL-C）试剂盒（批号：20121106），血清高密度脂

























































组别 绿原酸（X1） 栀子苷（X2） 生药量（mg·kg-1·d-1）
组1 15 45 60
组2 30 90 120
组3 45 30 75
组4 60 75 135
组5 75 15 90
组6 90 60 150
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正常组 6 2.83±0.72 1.32±0.12 0.43±0.12 1.93±0.41 38.77±8.24 32.98±6.28
模型组 7 6.34±1.21** 2.23±0.38** 1.42±0.21** 0.83±0.25** 87.32±31.22** 89.92±32.37**
组1 7 4.90±0.67 1.90±0.37 0.88±0.17 1.30±0.25 77.80±23.69 91.32±17.58
组2 7 4.55±0.66 1.68±0.07 0.72±0.10 1.28±0.11 48.00±11.73 68.13±11.92
组3 7 4.63±0.38 1.80±0.23 0.96±0.20 1.26±0.21 70.18±18.06 73.18±14.43
组4 7 4.10±0.70 1.76±0.18 0.77±0.10 1.33±0.17 39.45±9.25 61.51±13.17
组5 7 4.70±0.65 1.96±0.21 0.91±0.13 1.20±0.19 67.65±12.38 74.96±12.92




指标 回归方程 R P值 最优剂量配比
肝TG Y=4.896-233.911X1X2+3.174X2 0.983 0.000 绿原酸90mg+
栀子苷90mg
血清LDL-C Y=1.062-3.409X2-15.148X12 0.952 0.868
血清HDL-C Y=1.242+44.273X1X2 0.007 0.025
血清CHO Y=1.938-60.206X1X2 0.834 0.039
血清ALT Y=80.590-9 497.655X1X2 0.978 0.001







































































正常组 10 3.96±0.55 1.41±0.13 0.54±0.21 1.76±0.30 23.92±5.94 27.48±4.26
模型组 10 7.78±1.19** 2.07±0.36** 1.05±0.26** 1.08±0.32** 70.21±13.35** 91.60±23.62**
绿原酸组 10 6.45±0.67△ 1.82±0.38 0.77±0.23△ 1.31±0.63 48.93±6.79△ 44.85±11.46△△
栀子苷组 10 6.24±0.74△ 1.84±0.14 0.86±0.10 1.70±0.56△ 30.96±6.88△△ 38.68±13.81△△
绿原酸-栀子苷组 10 6.09±0.75△△ 1.67±0.16△ 0.78±0.16△ 1.51±0.19△ 28.96±7.88△△▲▲ 35.26±12.77△△
血脂康组 10 7.23±0.26□■ 1.88±0.29■ 0.78±0.09△ 1.24±0.54 34.07±8.15△△ 35.93±9.94△△
注：与正常组比较，**P<0.01；与模型组比较，△P<0.05，△△P<0.01；与绿原酸组比较，▲▲P<0.01；与栀子苷组比较，□P<0.05；与绿原酸-栀
子苷组比较，■P<0.05。
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图2 验证实验各组大鼠肝组织HE染色（×200）
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